GNOM vs IVV
Global X Genomics & Biotechnology ETF vs iShares Core S&P 500 ETF
Which is better, GNOM or IVV?
Mid Cap Growth against Large Cap Blend.
IVV has a lower expense ratio. GNOM led over 1Y, IVV over 3Y, 5Y and the full window. IVV is less concentrated, with 37.9% of the fund in its ten largest positions against 45.8%.
MarketXLS is not an investment adviser. This comparison is generated automatically from market data and is for information only. A Best mark means the better reading on that one measure, not a recommendation to buy.
Side-by-Side Comparison
| Metric | GNOM | IVV |
|---|---|---|
| Expense Ratio | 0.50% | 0.03%Best |
| AUM | $92M | $886.7B |
| Dividend Yield | 1.19% | 1.10% |
| Holdings | 52 | 508 |
| YTD Return | +40.86%Best | +13.39% |
| 1Y Return | +75.69%Best | +20.08% |
| 3Y Return (annualized) | +13.50% | +21.29%Best |
| 5Y Return (annualized) | -7.65% | +12.88%Best |
| Volatility (annualized) | 30.2% | 16.6%Best |
| Max Drawdown | -75.0% | -33.9%Best |
| $10,000 over 5 years | $6,717 | $18,327Best |
| Top 10 Weight | 45.8% | 37.9%Best |
| Fund Family | Global X by mirae Asset | iShares by BlackRock (US) |
| Category | Equity | Equity |
| Style | Mid Cap Growth | Large Cap Blend |
| Inception | Apr 5, 2019 | May 15, 2000 |
Volatility and max drawdown are measured over the window both funds cover: Apr 10, 2019 to Sep 4, 2026 (7.4 years).
GNOM vs IVV growth
Month-end closes. Both lines start at 0% in the first month shown, so the gap between them is the difference in growth across that window. The full view covers the 7.4 years both funds cover.
GNOM vs IVV Performance
Global X Genomics & Biotechnology ETF (GNOM) is an ETF from Global X by mirae Asset and iShares Core S&P 500 ETF (IVV) is an ETF from iShares by BlackRock (US). Over the past year GNOM returned +75.69% while IVV returned +20.08%. Year to date, GNOM is up 40.86% versus a gain of 13.39% for IVV.
Over three years, GNOM compounded at +13.50% per year against +21.29% for IVV; over five years the annualized figures are -7.65% and +12.88% respectively. Across the full 7-year window we track, IVV has the edge at +15.36% annualized vs +0.82%.
Past performance does not guarantee future results.
Risk: Volatility and Drawdowns
GNOM has been the more volatile fund, with annualized monthly volatility of 30.2% compared with 16.6% for IVV. Lower volatility generally means a smoother ride, though it often comes with lower long-run returns.
The deepest peak-to-trough decline in our data was -75.0% for GNOM and -33.9% for IVV. Drawdown depth is what each fund did in the worst stretch of the window measured above.
The two funds' monthly returns correlate at 0.62. They move together some of the time, and apart the rest.
Fees and Cost Over Time
GNOM charges 0.50% per year while IVV charges 0.03%. On a $10,000 position that is $50 vs $3 annually, a gap of $47 per year that compounds over a long holding period. On income, GNOM currently yields 1.19% against 1.10% for IVV.
Holdings Overlap
18.3% of GNOM's money is in holdings IVV also owns. 2.4% of IVV's money is in holdings GNOM also owns.
GNOM and IVV share little of their money.
9 positions in common, counted across the 50 positions we hold weights for in GNOM and 505 in IVV, against full books of 52 and 508.
What only one of them owns
Our book lists 488 positions for IVV that do not appear in our book for GNOM (97.0% of the fund), and 35 for GNOM that do not appear in IVV (66.1%).
Some of those will be the same company recorded under a different code in one of the two books, so the real difference in what you would own is no larger than this and may be smaller. We do not name the individual positions here for that reason.
Top Shared Holdings
| Stock | Weight in GNOM | Weight in IVV | Difference |
|---|---|---|---|
| TECHBio-Techne Corp | 4.23% | 0.02% | 4.21% |
| VRTXNvaesrtex Pharmaceuticals Inc | 3.76% | 0.18% | 3.58% |
| MRNAModerna therapeutics | 3.52% | 0.03% | 3.49% |
| LLYEli Lilly & Co. | 2.07% | 1.39% | 0.68% |
| GILDGilead Sciences | 1.75% | 0.25% | 1.50% |
| BMYBristol-Myers Squibb Co. | 1.18% | 0.20% | 0.98% |
| DHRDanaher Corporation | 1.11% | 0.19% | 0.92% |
| AAgilent Technologies Inc | 0.35% | 0.06% | 0.29% |
| DGXQuest Diagnostics Inc | 0.29% | 0.04% | 0.25% |
You are not choosing between two funds in isolation.
Whichever of GNOM and IVV you pick has to sit alongside everything else you own. Add the rest and see what the combination actually holds.
Free for up to 10 holdings. No account needed.
Frequently Asked Questions
Which is cheaper, GNOM or IVV?
GNOM has an expense ratio of 0.50% while IVV charges 0.03%. IVV is the cheaper option, by $47 a year on a $10,000 investment.
Which performed better, GNOM or IVV?
Over the past year GNOM returned +75.69% vs +20.08% for IVV, so GNOM leads on 1-year performance. Over the longest common window we track (7 years), GNOM annualized +0.82% vs +15.36% for IVV. Past performance does not guarantee future results. This is information, not a recommendation.
Which is riskier, GNOM or IVV?
GNOM has been the more volatile fund at 30.2% annualized versus 16.6% for IVV. Worst drawdown: GNOM -75.0% vs IVV -33.9%.
Should I hold both GNOM and IVV?
GNOM and IVV have a monthly-return correlation of 0.62, so their returns are far enough apart for the mix to behave differently from either one alone. This is information, not a recommendation.
What is the holdings overlap between GNOM and IVV?
18.3% of GNOM's money is in holdings IVV also owns. 2.4% of IVV's is in holdings GNOM also owns. They hold 9 positions in common, counted across the 50 positions we hold weights for in GNOM and 505 in IVV.
Which pays a higher dividend, GNOM or IVV?
GNOM yields 1.19% while IVV yields 1.10%, so GNOM currently pays the higher dividend yield.
Is IVV better than GNOM?
IVV has a lower expense ratio. GNOM led over 1Y, IVV over 3Y, 5Y and the full window. IVV is less concentrated, with 37.9% of the fund in its ten largest positions against 45.8%. Which one suits a particular account depends on what it is for. This is information, not a recommendation.